Actylis, a prominent global manufacturer and sourcing expert of critical materials and performance ingredients for the life sciences and specialty chemicals markets, has named Scott Thomson as its new Chief Executive Officer. Thomson brings a wealth of experience, having spent three decades in the pharmaceutical and chemical industries, with his most recent role being CEO of SPI Pharma. At SPI Pharma, he was instrumental in driving strategic development and sustainable improvement.
Before his tenure at SPI Pharma, Thomson held senior executive positions at BASF, where he managed several global life science and specialty ingredients businesses. His extensive background positions him well to steer Actylis towards further growth and innovation.
Rakesh Sachdev, Chairman of Actylis, expressed enthusiasm for Thomson’s appointment, recognizing his history of fostering long-term growth. Actylis aims to leverage Thomson’s expertise to enhance its client-centric, flexible customer service model and broaden its extensive product offerings across various geographies and applications.
Under Thomson’s leadership, Actylis plans to continue its expansion strategy, building upon its achievements both organically and through acquisitions. This approach aligns with the company’s goal to accelerate growth and solidify its market position.
Actylis has undergone significant transformation since New Mountain Capital’s investment in 2019, evolving into a leading manufacturer and distributor of essential ingredients across the pharma, biopharma, nutritional, agri-science, cosmetics, and specialty chemicals markets. The company has completed seven acquisitions, significantly expanding its global reach.
With a rapidly growing portfolio of GMP and non-GMP facilities worldwide and a strong sourcing partner network, Actylis provides flexible and reliable solutions tailored to customers’ unique manufacturing requirements. The company’s hybrid manufacturing and global sourcing model ensures industry-leading standards of quality documentation and regulatory compliance.
Actylis, headquartered in Port Washington, New York, operates in 10 countries across three continents, offering more than 4,000 products supported by over 800 employees. With over 75 years of experience, Actylis serves a diverse range of markets, including pharmaceutical, biopharmaceutical, nutritional, cosmetics, agri-science, and specialty chemicals.
New Mountain Capital, the investment firm backing Actylis, emphasizes business growth and value creation over debt. Managing approximately $50 billion in assets, New Mountain Capital focuses on identifying high-quality growth leaders in select industry sectors and collaborates intensively with management teams to enhance the value of its portfolio companies.
